Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Meningococcal Vaccine”

384 trials

Showing 20 of 384 results

Large-scale testing (Phase 3)Study completedNCT00657709
What this trial is testing

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Who this might be right for
Serogroup B Meningococcal Meningitis
Novartis Vaccines 3,630
Post-approval studies (Phase 4)Study completedNCT01430611
What this trial is testing

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Who this might be right for
Meningococcal DiseaseMeningitis
Sanofi Pasteur, a Sanofi Company 666
Testing effectiveness (Phase 2)Study completedNCT00129116
What this trial is testing

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 388
Large-scale testing (Phase 3)Study completedNCT00464815
What this trial is testing

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 1,025
Testing effectiveness (Phase 2)Study completedNCT01026974
What this trial is testing

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Who this might be right for
Meningococcal Disease
Novartis Vaccines 120
Testing effectiveness (Phase 2)Study completedNCT01434680
What this trial is testing

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis 992
Large-scale testing (Phase 3)Study completedNCT01214850
What this trial is testing

Novartis Vaccine and Diagnostics Carriage Trial

Who this might be right for
N. Meningitidis Carriage
Novartis Vaccines 2,968
Large-scale testing (Phase 3)Study completedNCT02003313
What this trial is testing

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

Who this might be right for
Meningitis
Beijing Minhai Biotechnology Co., Ltd 1,260
Testing effectiveness (Phase 2)Study completedNCT01461993
What this trial is testing

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Who this might be right for
VaccinesMeningococcal Vaccines
Pfizer 2,499
Post-approval studies (Phase 4)Study completedNCT00310687
What this trial is testing

Persistence of Immune Response After Vaccination With MCC

Who this might be right for
Prevention of Meningococcal Infection
Novartis 1,244
Post-approval studies (Phase 4)Study completedNCT00392808
What this trial is testing

Immunogenicity of the Booster Dose of Two MenC Vaccines

Who this might be right for
Meningococcal Infection
Centro Superior de Investigación en Salud Publica 389
Large-scale testing (Phase 3)Study completedNCT01000311
What this trial is testing

Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

Who this might be right for
Meningococcal Disease
Novartis Vaccines 529
Large-scale testing (Phase 3)Study completedNCT00974363
What this trial is testing

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 697
Large-scale testing (Phase 3)Study completedNCT00345683
What this trial is testing

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Who this might be right for
Haemophilus Influenzae Type bNeisseria Meningitidis
GlaxoSmithKline 4,021
Large-scale testing (Phase 3)Study completedNCT03621670
What this trial is testing

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 1,196
Testing effectiveness (Phase 2)Study completedNCT00310856
What this trial is testing

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Who this might be right for
Meningococcal Meningitis
Novartis Vaccines 175
Testing effectiveness (Phase 2)Study completedNCT01992536
What this trial is testing

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Who this might be right for
Meningococcal Disease
Novartis Vaccines 194
Testing effectiveness (Phase 2)Study completedNCT04886154
What this trial is testing

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 1,440
Large-scale testing (Phase 3)Study completedNCT01235975
What this trial is testing

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 400
Not applicableStudy completedNCT02500511
What this trial is testing

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Who this might be right for
Meningococcal MeningitisMeningococcal Infections
JN-International Medical Corporation 50
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation